单倍体造血干细胞移植供者选择研究进展  

Progress of donor selection of haploidentical hematopoietic stem cell transplantation

作　　者：冯媛[1] 李建勇[1] 缪扣荣[1] Feng Yuan;Li Jianyong;Miao Kourong(Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院,江苏省人民医院血液科,210029

出　　处：《白血病．淋巴瘤》2020年第6期374-377,共4页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金(81470329)。

摘　　要：单倍体造血干细胞移植(HID-HSCT)作为治疗血液系统疾病的一种重要方法,目前在全世界范围得到越来越多的关注。新治疗方案和药物的出现不断改善治疗效果、给患者带来更多的获益。慎重选择合适的供者可优化临床结局,而选择最佳供者时需要考虑诸多影响因素,如受体中的供体特异性抗体、供体年龄、亲缘关系、性别、ABO血型兼容性、人类白细胞抗原(HLA)不匹配的程度、自然杀伤(NK)细胞同种异体反应和供受者巨细胞病毒(CMV)血清状态等。文章就HID-HSCT供者选择的最新进展情况进行阐述。Haploidentical hematopoietic stem cell transplantation(HID-HSCT)is increasingly used worldwide as an important treatment for hematopoietic diseases.Thanks to the improvements in new treatment regimens and drugs,more patients with hematopoietic disorders can benefit from it.Selecting the appropriate donor is good to optimize clinical outcomes.Many factors need to be taken into consideration when choosing the optimum donor,such as donor-specific antibodies,donor age,genetic relationship,gender and ABO compatibility,human lymphocyte antigen(HLA)mismatch,natural killer cell alloreactivity,and serum status of donor cytomegalovirus.This article reviews the new progress of donor selection of HID-HSCT.

关 键 词：血液肿瘤 造血干细胞移植 单倍性 危险因素 

分 类 号：R457.7[医药卫生—治疗学]